A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a threat if they were to begin spreading in people.
Texas Biomedical Research InstituteSep 6 2024 The antibody, called SC27, was recently described in Cell Reports Medicine .
Monoclonal antibody SC27 was identified, developed and provisionally patented by a team of researchers led by Greg Ippolito, Ph.D., who recently joined Texas Biomedical Research Institute from University of Texas at Austin. Other team leaders included Jason Lavinder, Ph.D., at UT and Ralph Baric, Ph.D., at University of North Carolina at Chapel Hill.
The researchers tested SC27 against 12 viruses, from the original SARS-CoV-2 to currently circulating variants, as well as related SARS-1 and several other coronaviruses found in bats and pangolins. The antibody was effective against all of them in a petri dish and protected mice against both variants tested.
The team is looking to collaborate with industry to further develop the SC27 monoclonal antibody treatment, which could potentially benefit immunocompromised patients who are unable to get vaccines. It also could serve as an emergency treatment during future outbreaks of new variants or coronaviruses.
Antibodies Cell Covid-19 Medicine Monoclonal Antibody Ph Preclinical Protein Research SARS SARS-Cov-2 Spike Protein Vaccine Virus
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Study unveils novel treatment for blocking SARS-CoV-2 entry into cellsIn light of the ongoing threat posed by new viruses following the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which led to the COVID-19 pandemic, new antiviral drugs continue to be developed to effectively block viral entry into the human body.
Read more »
Obesity increases the risk of SARS-CoV-2 infection by 34%Obesity is linked to a 34% higher risk of SARS-CoV-2 infection upon exposure, highlighting the importance of weight management in COVID-19 prevention.
Read more »
Study finds higher SARS-CoV-2 risk in obese individualsA study finds an increased risk of developing a productive SARS-CoV-2 infection in obese people. Obesity is known to predict worse outcomes and higher mortality for those with COVID-19. Masanori Aikawa and colleagues sought to determine if obesity also affected the likelihood of getting ill in the first place.
Read more »
SARS-CoV-2 evolves differently in the brain, revealing critical insights into viral tropismStudy investigates the evolution of SARS-CoV-2 within the central nervous system (CNS) compared to the lungs in mice, revealing higher viral divergence in the CNS and highlighting the critical role of the furin cleavage site (FCS) in viral tropism and compartmentalization.
Read more »
Intranasal vaccine shows broad SARS-CoV-2 variant protectionStudy demonstrates that a single-dose intranasal live-attenuated vaccine, CDO-7N-1, provides broad protection against SARS-CoV-2 and its variants by inducing potent immune responses, including neutralizing antibodies and T-cell activity, in animal models.
Read more »
Newly discovered antibody can neutralize all known variants of SARS-CoV-2Researchers have discovered an antibody able to neutralize all known variants of SARS-CoV-2, the virus that causes COVID-19, as well as distantly related SARS-like coronaviruses that infect other animals.
Read more »